Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DPDIMP#1-trial
2024-518448-20-00Phase 4Completed
- Sponsor
- Helsinki University Hospital
- Start
- Oct 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of tegafur, capecitabine and fluorouracil in breast cancer and colon cancer, sponsored by Helsinki University Hospital. Primary endpoint: Plasma and fingertip capillary pharmacokinetics of fluoropyrimidines. Started Oct 2024; status: completed.
02
Drugs
tegafurcapecitabinefluorouracil
03
Conditions
breast cancercolon cancer
Beyond the preview
Go deeper on 2024-518448-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518448-20-00.